

AR47

1. Niraparib, abiraterone acetate, and prednisone for use in a method for treating a prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of niraparib, a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of prednisone, wherein the patient has a DNA repair anomaly in at least one gene selected from the group consisting of BRCA-1 and BRCA-2, and wherein the gene has a genomic lesion selected from the group consisting of:

(i) homozygous deletion,

(ii) heterozygous deletion + deleterious mutation, and

(iii) copy neutral loss of heterozygosity + deleterious mutation.

2. The niraparib, abiraterone acetate, and prednisone for use according to claim 1, wherein the prostate cancer is hormone-sensitive or castration-resistant prostate cancer.

3. The niraparib, abiraterone acetate, and prednisone for use according to claim 1 or 2, wherein niraparib is administered in a separate composition from abiraterone acetate, wherein niraparib is administered in a separate composition from the abiraterone acetate and prednisone, wherein the prednisone is administered in a separate composition to the niraparib and abiraterone acetate, or wherein niraparib, abiraterone acetate and prednisone are each administered in separate compositions.

4. The niraparib, abiraterone acetate, and prednisone for use according to any preceding claim, wherein niraparib and abiraterone acetate are each administered once daily to the patient.

5. The niraparib, abiraterone acetate, and prednisone for use according to ~~any preceding claim 2,~~ comprising administering about 500 to about 1500 mg/day, ~~about 600 to about 1300 mg/day, or about 900 to about 1100 mg/day~~ of the abiraterone acetate to the patient.

6. The niraparib, abiraterone acetate, and prednisone for use according to claim 5, comprising administering about 1000 mg/day or about 500 mg/day of the abiraterone acetate to the patient.

7. The niraparib, abiraterone acetate, and prednisone for use according to ~~any of claims 1 to 5,~~ comprising administering about 30 to about 400 mg/day, ~~about 100 to about 300 mg/day, or about 175 to about 225 mg/day~~ of the niraparib to the patient.

8. The niraparib, abiraterone acetate, and prednisone for use according to claim 6, comprising administering about 200 mg/day of the niraparib to the patient.

9. The niraparib, abiraterone acetate, and prednisone for use according to ~~any of claims 1 to 4-~~